-
Pullarkat, VA, Stock, W, Lacayo, NJ, Jabbour, E, Bajel, A, Rubnitz, J, Leonard, J, Mullighan, CG, Khaw, SL, Vear, SI, et al.
PS940 COMBINATION BCL‐2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA.
HemaSphere
3(S1)
:
423 -424
2019
view publication
-
Moujalled, DM, Hanna, DT, Pomilio, G, Litalien, V, Fleming, S, Chanrion, M, Maragno, A-L, Kraus-Berthier, L, Khaw, SL, Lessene, G, et al.
Identification of Potent BH3-Mimetic Combinations Targeting Pro-Survival Pathways in Human B-Cell Acute Lymphoblastic Leukemia.
Blood
132(Supplement 1)
:
567
2018
view publication
-
Alexander, T, Lacayo, NJ, Pullarkat, VA, Jabbour, EJ, Khaw, SL, Mullighan, CG, Bajel, A, Leonard, J, Norris, R, Rubnitz, J, et al.
Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Blood
132(Supplement 1)
:
3966
2018
view publication
-
Chin, HS, Li, MX, Tan, IKL, Ninnis, RL, Reljic, B, Scicluna, K, Dagley, LF, Sandow, JJ, Kelly, GL, Samson, AL, et al.
VDAC2 enables BAX to mediate apoptosis and limit tumor development..
Nat Commun
9(1)
:
4976
2018
view publication
-
Hantel, A, Wynne, J, Lacayo, N, Khaw, SL, Rubnitz, J, Mullighan, C, Schmidt, M, Zhou, Y, Ross, JA, Rosenwinkel, L, et al.
Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Clinical Lymphoma Myeloma & Leukemia
18:
s184 -s185
2018
view publication